Drugs improvement to combat Trypanosomatidic infections

Drugs improvement to combat Trypanosomatidic infections

If you live in Europe, you may never have heard of 'neglected diseases' from Trypanosomatidic infections. However, in countries like Brazil or Sudan these diseases are endemic.

Neglected diseases are conditions that inflict severe health burdens on the world's poorest people, and they are said to be 'neglected' because they are often overlooked by drug developers. Leishmaniasis, sleeping sickness and represent a huge problem in the lives of people who are affected. Existing drugs to treat them are simply inadequate, presenting problems like inefficient delivery, insufficient efficacy, excessive toxicity and increasing resistance. Experts say that are urgently needed to address the problem.

NMTRYPI ('New Medicines for Trypanosomatidic Infections') a consortium of nine EU academic institutes and four SMEs, recently launched a programme to answer this call by optimising anti-trypanosomal drugs. The NMTRYPI partners are already well familiar with the anti-trypanosomal drugs in question because they were previously responsible for discovering them. Now, they will build on that work by attempting to progress the lead compounds in these drugs as well as screening fungal natural products and Sudanese medicinal plants to discover new lead compounds for development.

Over the next three years, NMTRYPI's interdisciplinary team will use a common drug discovery platform, established by experts in their respective fields, to develop drug leads which may be used in combination with other drugs. The partners will also work to develop pharmacodynamic biomarkers that enable the proteomic profiling of compound efficacy and early identification of . The platform used by NMTRYPI enables high throughput screening of compound libraries, leads to candidate drugs development, proof of concept testing, and toxicology and safety testing. It will ultimately allow the NMTRYPI team to translate drug leads into drug candidates to enter the international development pipelines.

Neglected diseases like leishmaniasis, sleeping sickness and chagas disease are most prevalent in tropical climates, particularly in areas with unsafe drinking water, poor sanitation, sub-standard housing and little or no access to health care. Unfortunately, can often also lack visibility because they usually do not cause dramatic outbreaks that kill large numbers of people. Rather, they usually exact their toll over a longer period of time, leading to crippling deformities, severe disabilities and/or relatively slow deaths.

More information: For more information, see cordis.europa.eu/projects/rcn/109924_en.html

Related Stories

Crowdfunding drug discovery

date Oct 29, 2013

During his nine years working in the pharmaceutical industry, Michael Pollastri learned to protect his research and data with extreme caution. "In the drug industry, everything is super secret," said Pollastri, now an associate ...

Recommended for you

MSF fighting cholera outbreak in Tanzania refugee camps

date 9 hours ago

Medical charity Medecins sans Frontieres (MSF, Doctors Without Borders) said Sunday it had launched emergency treatment centres in Tanzania, where thousands of Burundians fleeing unrest have been hit by cholera.

Bacteria blamed in indigenous Mexican baby deaths

date May 23, 2015

Bacteria—and not a contaminated vaccine as initially suspected—were to blame for the recent deaths of two Mexican babies and for sickening 29 others, according to an official investigation.

Explainer: What is Chagas disease?

date May 22, 2015

According to an article in the Journal of the American Medical Association (JAMA), in a Los Angeles clinic treating patients with heart failure, about 20% of Latin American patients have Chagas disease. What is that?, y ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.